Showing results (951-960 of 1,242) with videos related to

Sort By:
Pageof 125
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 5, 2021
Early juvenile reading epilepsy and later frontotemporal dementia (FTD): expanding the clinical phenotype of C9ORF72 mutation?Marta Melis, Giovanni Defazio, Elisa Casaglia, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 17, 2020
Total serum immunoglobulin A in ALSJesse Crayle, Mai Elmallah, John Sleasman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 4, 2025
A VAPB (P56S) mutation in a Dutch patient with familial motor neuron disease: a case reportSean W Willemse, Koen C Demaegd, Ruben P A Van Eijk, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 30, 2015
The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosisElizabeth Gray, James R Larkin, Tim D W Claridge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 19, 2016
Transcultural validation of the ALS-CBS Cognitive Section for the Brazilian populationLucas M T Branco, Tamires Zanao, Thiago J De Rezende, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 23, 2018
Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North AmericaLu Tang, Yan Ma, Xiaolu Liu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 6, 2017
Sympathetic vascular response to facial cooling is increased in flail phenotypes of amyotrophic lateral sclerosisMarcin Tutaj, MaŁgorzata Miller, Barbara Tomik, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populationsYoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosisKoji Takei, Kikumi Tsuda, Fumihiro Takahashi, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studiesAlexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki, et al.
Pageof 125